Medical aesthetics practices and spas nationwide are increasingly considering adding glucagon-like peptide 1 (GLP-1) and other weight loss drugs to their service offerings. While these treatments present significant financial opportunities, they also introduce complex legal risks that practices, spas, and affiliated management services organizations (MSOs) must carefully evaluate. To help, Frier Levitt partner Brandon Zarsky published an article on this topic in Modern Aesthetics titled, “Legal Issues to Consider When Implementing GLP-1 and Other Weight Loss Drugs into Your Medical Aesthetics Business.” The piece outlines key legal compliance and risk management considerations for integrating GLP-1 and other weight-loss drugs, helping aesthetics businesses navigate regulatory challenges and mitigate risks.
Additionally, Brandon shares essential tips for marketing GLP-1 in consideration of federal laws and regulations. He also sheds light on different state limitations for treatment using GLP-1.
Topics include:
- Marketing Considerations
- Telehealth and Telemedicine Requirements
- Scope Of Practice and Supervision Requirements
- Other State-Specific Laws and Regulations
- Compounding Considerations
